Advances in Immune Factors of Recurrent Implantation Failure

doi:10.12280/gjszjk.20200352

Abstract

Abstract:

With the development of assisted reproductive technology, the pregnancy rate has been increasing year by year, but some patients still suffer from recurrent implantation failure (RIF). To some extent RIF is a limiting factor of the success of in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The mechanism of RIF is still unclear, and common causes include the defects in embryo quality, the decreased endometrial receptivity and so on. Pregnancy is a process in which "allograft" embryos invade the endometrium. With the development of reproductive immunology, people pay more and more attention to the significant role of immune factors in RIF. The immune events in maternal-fetal interface during early pregnancy are extremely complex, involving a large number of immune cells and molecules. There is also a close relationship between the IVF/ICSI outcome and autoimmune antibody. A growing number of studies have shown that immunological factors may be the main cause of RIF with unknown causes. This article summarizes the immunological factors of RIF and the common immunotherapy for RIF.

Key words: Embryo transfer, Embryo implantation, Immune tolerance, Autoantibodies, Immunotherapy

ZHOU Yu-xi, XIE Qi-jun, SHEN Rong, LING Xiu-feng, ZHAO Chun. Advances in Immune Factors of Recurrent Implantation Failure[J]. Journal of International Reproductive Health/Family Planning, 2021, 40(2): 147-152.

References 39

[1]	刘道英, 张建伟. 反复种植失败诊断标准的研究进展[J]. 国际生殖健康/计划生育杂志, 2019,38(5):397-400. doi: 10.3969/j.issn.1674-1889.2019.05.010.
[2]	Polanski LT, Baumgarten MN, Quenby S, et al. What exactly do we mean by ′recurrent implantation failure′? A systematic review and opinion[J]. Reprod Biomed Online, 2014,28(4):409-423. doi: 10.1016/j.rbmo.2013.12.006. doi: 10.1016/j.rbmo.2013.12.006 URL
[3]	Beer AE, Kwak JY, Ruiz JE. Immunophenotypic profiles of peripheral blood lymphocytes in women with recurrent pregnancy losses and in infertile women with multiple failed in vitro fertilization cycles[J]. Am J Reprod Immunol, 1996,35(4):376-382. doi: 10.1111/j.1600-0897.1996.tb00497.x. doi: 10.1111/j.1600-0897.1996.tb00497.x URL pmid: 8739457
[4]	Kolanska K, Suner L, Cohen J, et al. Proportion of Cytotoxic Peripheral Blood Natural Killer Cells and T-Cell Large Granular Lymphocytes in Recurrent Miscarriage and Repeated Implantation Failure: Case-Control Study and Meta-analysis[J]. Arch Immunol Ther Exp (Warsz), 2019,67(4):225-236. doi: 10.1007/s00005-019-00546-5. doi: 10.1007/s00005-019-00546-5 URL
[5]	Chernyshov VP, Dons′koi BV, Sudoma IO, et al. Comparison of T and NK lymphocyte subsets between human endometrial tissue and peripheral blood[J]. Cent Eur J Immunol, 2019,44(3):316-321. doi: 10.5114/ceji.2019.89610. doi: 10.5114/ceji.2019.89610 URL pmid: 31871420
[6]	Jena MK, Nayak N, Chen K, et al. Role of Macrophages in Pregnancy and Related Complications[J]. Arch Immunol Ther Exp (Warsz), 2019,67(5):295-309. doi: 10.1007/s00005-019-00552-7. doi: 10.1007/s00005-019-00552-7 URL
[7]	Girardi G. Complement activation, a threat to pregnancy[J]. Semin Immunopathol, 2018,40(1):103-111. doi: 10.1007/s00281-017-0645-x. doi: 10.1007/s00281-017-0645-x URL pmid: 28900713
[8]	Chow WN, Lee YL, Wong PC, et al. Complement 3 deficiency impairs early pregnancy in mice[J]. Mol Reprod Dev, 2009,76(7):647-655. doi: 10.1002/mrd.21013. doi: 10.1002/mrd.21013 URL pmid: 19205046
[9]	Ghasemnejad-Berenji H, Ghaffari Novin M, Hajshafiha M, et al. Immunomodulatory effects of hydroxychloroquine on Th1/Th2 balance in women with repeated implantation failure[J]. Biomed Pharmacother, 2018,107:1277-1285. doi: 10.1016/j.biopha.2018.08.027. doi: 10.1016/j.biopha.2018.08.027 URL pmid: 30257342
[10]	Robertson SA, Care AS, Moldenhauer LM. Regulatory T cells in embryo implantation and the immune response to pregnancy[J]. J Clin Invest, 2018,128(10):4224-4235. doi: 10.1172/JCI122182. doi: 10.1172/JCI122182 URL pmid: 30272581
[11]	Ahmadi M, Abdolmohamadi-Vahid S, Ghaebi M, et al. Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind, phase II randomized clinical trial[J]. Int Immunopharmacol, 2019,74:105730. doi: 10.1016/j.intimp.2019.105730. doi: 10.1016/j.intimp.2019.105730 URL pmid: 31299610
[12]	Muyayalo KP, Li ZH, Mor G, et al. Modulatory effect of intravenous immunoglobulin on Th17/Treg cell balance in women with unexplained recurrent spontaneous abortion[J]. Am J Reprod Immunol, 2018,80(4):e13018. doi: 10.1111/aji.13018. doi: 10.1111/aji.13018 URL pmid: 29984444
[13]	Coulam CB, Acacio B. Does immunotherapy for treatment of reproductive failure enhance live births?[J]. Am J Reprod Immunol, 2012,67(4):296-304. doi: 10.1111/j.1600-0897.2012.01111.x. doi: 10.1111/j.1600-0897.2012.01111.x URL
[14]	Kim NY, Cho HJ, Kim HY, et al. Thyroid autoimmunity and its association with cellular and humoral immunity in women with reproductive failures[J]. Am J Reprod Immunol, 2011,65(1):78-87. doi: 10.1111/j.1600-0897.2010.00911.x. doi: 10.1111/j.1600-0897.2010.00911.x URL
[15]	Łukaszuk K, Kunicki M, Kulwikowska P, et al. The impact of the presence of antithyroid antibodies on pregnancy outcome following intracytoplasmatic sperm injection-ICSI and embryo transfer in women with normal thyreotropine levels[J]. J Endocrinol Invest, 2015,38(12):1335-1343. doi: 10.1007/s40618-015-0377-5. doi: 10.1007/s40618-015-0377-5 URL pmid: 26280321
[16]	Rao M, Zeng Z, Zhao S, et al. Effect of levothyroxine supplementation on pregnancy outcomes in women with subclinical hypothyroidism and thyroid autoimmuneity undergoing in vitro fertilization/intracytoplasmic sperm injection: an updated meta-analysis of randomized controlled trials[J]. Reprod Biol Endocrinol, 2018,16(1):92. doi: 10.1186/s12958-018-0410-6. doi: 10.1186/s12958-018-0410-6 URL pmid: 30249251
[17]	Akhtar MA, Agrawal R, Brown J, et al. Thyroxine replacement for subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism[J]. Cochrane Database Syst Rev, 2019,6(6):CD011009. doi: 10.1002/14651858.CD011009.pub2.
[18]	Ying Y, Zhong YP, Zhou CQ, et al. Antinuclear antibodies predicts a poor IVF-ET outcome: impaired egg and embryo development and reduced pregnancy rate[J]. Immunol Invest, 2012,41(5):458-468. doi: 10.3109/08820139.2012.660266. doi: 10.3109/08820139.2012.660266 URL
[19]	Kekow M, Barleben M, Drynda S, et al. Long-term persistence and effects of fetal microchimerisms on disease onset and status in a cohort of women with rheumatoid arthritis and systemic lupus erythematosus[J]. BMC Musculoskelet Disord, 2013,14:325. doi: 10.1186/1471-2474-14-325. doi: 10.1186/1471-2474-14-325 URL pmid: 24245522
[20]	Li Y, Wang Y, Ma Y, et al. Investigation of the impact of antinuclear antibody on the outcome of in vitro fertilization/intracytoplasmic sperm injection treatment[J]. Taiwan J Obstet Gynecol, 2015,54(6):742-748. doi: 10.1016/j.tjog.2015.09.001. doi: 10.1016/j.tjog.2015.09.001 URL pmid: 26700996
[21]	Ying Y, Guo X, Zhong Y, et al. An Exploration of the Impact of Anticentromere Antibody on Early-Stage Embryo[J]. J Immunol Res, 2017,2017:4809294. doi: 10.1155/2017/4809294. doi: 10.1155/2017/4809294 URL pmid: 29119119
[22]	Potdar N, Gelbaya TA, Konje JC, et al. Adjunct low-molecular-weight heparin to improve live birth rate after recurrent implantation failure: a systematic review and meta-analysis[J]. Hum Reprod Update, 2013,19(6):674-684. doi: 10.1093/humupd/dmt032. doi: 10.1093/humupd/dmt032 URL
[23]	Chen X, Mo ML, Huang CY, et al. Association of serum autoantibodies with pregnancy outcome of patients undergoing first IVF/ICSI treatment: A prospective cohort study[J]. J Reprod Immunol, 2017,122:14-20. doi: 10.1016/j.jri.2017.08.002. doi: 10.1016/j.jri.2017.08.002 URL pmid: 28804023
[24]	罗希, 周从容, 黄永俐, 等. 早期抗凝干预治疗对冻融胚胎移植前高D-二聚体患者妊娠结局的影响[J]. 国际生殖健康/计划生育杂志, 2019,38(2):104-107. doi: 10.3969/j.issn.1674-1889.2019.02.003.
[25]	Lédée N, Prat-Ellenberg L, Petitbarat M, et al. Impact of prednisone in patients with repeated embryo implantation failures: Beneficial or deleterious?[J]. J Reprod Immunol, 2018,127:11-15. doi: 10.1016/j.jri.2018.03.003. doi: 10.1016/j.jri.2018.03.003 URL pmid: 29627619
[26]	Zhang T, Huang C, Du Y, et al. Successful treatment with intrauterine delivery of dexamethasone for repeated implantation failure[J]. Am J Reprod Immunol, 2017,78(6). doi: 10.1111/aji.12766. doi: 10.1111/aji.12758 URL pmid: 28921706
[27]	Fan J, Zhong Y, Chen C. Combined treatment of prednisone and aspirin, starting before ovulation induction, may improve reproductive outcomes in ANA-positive patients[J]. Am J Reprod Immunol, 2016,76(5):391-395. doi: 10.1111/aji.12559. doi: 10.1111/aji.12559 URL pmid: 27618792
[28]	Pasquier E, de Saint-Martin L, Marhic G, et al. Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study[J]. BMJ Open, 2019,9(3):e025649. doi: 10.1136/bmjopen-2018-025649. doi: 10.1136/bmjopen-2018-025649 URL pmid: 30898821
[29]	Klinger G, Morad Y, Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases[J]. Lancet, 2001,358(9284):813-814. doi: 10.1016/S0140-6736(01)06004-4. doi: 10.1016/S0140-6736(01)06004-4 URL pmid: 11564493
[30]	Azizi R, Ahmadi M, Danaii S, et al. Cyclosporine A improves pregnancy outcomes in women with recurrent pregnancy loss and elevated Th1/Th2 ratio[J]. J Cell Physiol, 2019,234(10):19039-19047. doi: 10.1002/jcp.28543. doi: 10.1002/jcp.28543 URL pmid: 30924169
[31]	Du MR, Zhou WH, Piao HL, et al. Cyclosporin A promotes crosstalk between human cytotrophoblast and decidual stromal cell through up-regulating CXCL12/CXCR4 interaction[J]. Hum Reprod, 2012,27(7):1955-1965. doi: 10.1093/humrep/des111. doi: 10.1093/humrep/des111 URL
[32]	Zhou WH, Du MR, Dong L, et al. Cyclosporin A increases expression of matrix metalloproteinase 9 and 2 and invasiveness in vitro of the first-trimester human trophoblast cells via the mitogen-activated protein kinase pathway[J]. Hum Reprod, 2007,22(10):2743-2750. doi: 10.1093/humrep/dem097. doi: 10.1093/humrep/dem097 URL pmid: 17566014
[33]	Ahmadi M, Abdolmohammadi-Vahid S, Ghaebi M, et al. Effect of Intravenous immunoglobulin on Th1 and Th2 lymphocytes and improvement of pregnancy outcome in recurrent pregnancy loss (RPL)[J]. Biomed Pharmacother, 2017,92:1095-1102. doi: 10.1016/j.biopha.2017.06.001. doi: 10.1016/j.biopha.2017.06.001 URL pmid: 28622710
[34]	Ahmadi M, Abdolmohammadi-Vahid S, Ghaebi M, et al. Regulatory T cells improve pregnancy rate in RIF patients after additional IVIG treatment[J]. Syst Biol Reprod Med, 2017,63(6):350-359. doi: 10.1080/19396368.2017.1390007. doi: 10.1080/19396368.2017.1390007 URL pmid: 29099629
[35]	Kalem Z, Namli Kalem M, Bakirarar B, et al. Intrauterine G-CSF Administration in Recurrent Implantation Failure (RIF): An Rct[J]. Sci Rep, 2020,10(1):5139. doi: 10.1038/s41598-020-61955-7. doi: 10.1038/s41598-020-61955-7 URL pmid: 32198409
[36]	Liu X, Ma D, Wang W, et al. Intrauterine administration of human chorionic gonadotropin improves the live birth rates of patients with repeated implantation failure in frozen-thawed blastocyst transfer cycles by increasing the percentage of peripheral regulatory T cells[J]. Arch Gynecol Obstet, 2019,299(4):1165-1172. doi: 10.1007/s00404-019-05047-6. doi: 10.1007/s00404-019-05047-6 URL pmid: 30659362
[37]	Xie H, Zeng H, He D, et al. Effect of intrauterine perfusion of human chorionic gonadotropin before embryo transfer after two or more implantation failures: A systematic review and meta-analysis[J]. Eur J Obstet Gynecol Reprod Biol, 2019,243:133-138. doi: 10.1016/j.ejogrb.2019.10.039. doi: 10.1016/j.ejogrb.2019.10.039 URL pmid: 31704529
[38]	Volovsky M, Healey M, MacLachlan V, et al. Should intrauterine human chorionic gonadotropin infusions ever be used prior to embryo transfer?[J]. J Assist Reprod Genet, 2018,35(2):273-278. doi: 10.1007/s10815-017-1049-5. doi: 10.1007/s10815-017-1049-5 URL pmid: 28948440
[39]	Winger EE, Reed JL, Ashoush S, et al. Degree of TNF-α/IL-10 cytokine elevation correlates with IVF success rates in women undergoing treatment with Adalimumab (Humira) and IVIG[J]. Am J Reprod Immunol, 2011,65(6):610-618. doi: 10.1111/j.1600-0897.2010.00946.x. doi: 10.1111/j.1600-0897.2010.00946.x URL